- Home
- QTWO vs PCVX Comparison
QTWO vs PCVX Comparison
Compare QTWO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTWO
- PCVX
- Stock Information
- Founded
- QTWO 2004
- PCVX 2013
- Country
- QTWO United States
- PCVX United States
- Employees
- QTWO N/A
- PCVX N/A
- Industry
- QTWO Computer Software: Prepackaged Software
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- QTWO Technology
- PCVX Health Care
- Exchange
- QTWO Nasdaq
- PCVX Nasdaq
- Market Cap
- QTWO 4.5B
- PCVX 4.5B
- IPO Year
- QTWO 2014
- PCVX 2020
- Fundamental
- Price
- QTWO $89.54
- PCVX $31.16
- Analyst Decision
- QTWO Buy
- PCVX Strong Buy
- Analyst Count
- QTWO 15
- PCVX 10
- Target Price
- QTWO $101.43
- PCVX $136.50
- AVG Volume (30 Days)
- QTWO 581.5K
- PCVX 2.2M
- Earning Date
- QTWO 05-07-2025
- PCVX 05-07-2025
- Dividend Yield
- QTWO N/A
- PCVX N/A
- EPS Growth
- QTWO N/A
- PCVX N/A
- EPS
- QTWO N/A
- PCVX N/A
- Revenue
- QTWO $720,691,000.00
- PCVX N/A
- Revenue This Year
- QTWO $13.62
- PCVX N/A
- Revenue Next Year
- QTWO $10.43
- PCVX N/A
- P/E Ratio
- QTWO N/A
- PCVX N/A
- Revenue Growth
- QTWO 13.12
- PCVX N/A
- 52 Week Low
- QTWO $55.97
- PCVX $27.66
- 52 Week High
- QTWO $112.82
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- QTWO 67.85
- PCVX 36.73
- Support Level
- QTWO $78.23
- PCVX $28.09
- Resistance Level
- QTWO $91.77
- PCVX $33.75
- Average True Range (ATR)
- QTWO 2.48
- PCVX 2.54
- MACD
- QTWO 1.44
- PCVX 1.12
- Stochastic Oscillator
- QTWO 87.60
- PCVX 35.61
About QTWO Q2 Holdings Inc.
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.